Pathos AI Announces Wednesday August 5 a $2.09 Billion Licensing Deal With Jiangsu Alphamab Biopharmaceuticals Co. Ltd. for a TROP2/HER3 Bispecific Antibody-Drug Conjugate (ADC), Extending the ADC Modality Deal-Making Cycle That Has Produced Substantial Cross-Border Capital Deployment Across 2025-2026 Including Merck's Chugai Deal, AbbVie's ImmunoGen Acquisition, Pfizer's Seagen Acquisition Legacy, and the Emerging Peptide-Drug Conjugate (PDC) Franchise Alongside Novartis-Myricx's $1.5 Billion Peptide-Drug-Conjugate Alliance Announced July 6
Pathos AI announced Wednesday August 5, 2026 a $2.09 billion licensing deal with Jiangsu Alphamab Biopharmaceuticals Co. Ltd. for a TROP2/HER3 bispecific antibody-drug conjugate (ADC). The deal extends the ADC modality deal-making cycle that has produced substantial cross-border capital deployment across 2025-2026, notably including Merck's Chugai ADC franchise deal, AbbVie's 2023 ImmunoGen acquisition, the ongoing Pfizer-Seagen (Seattle Genetics) commercial integration, and the emerging peptide-drug conjugate (PDC) franchise developments. The Pathos AI-Alphamab deal complements the July 6 Novartis-Myricx $1.5 billion peptide-drug-conjugate alliance (upfront + biobucks) covered on the site's July digest. TROP2 (trophoblast cell surface antigen 2) is a well-validated oncology target with existing approved ADCs including AstraZeneca-Daiichi Sankyo's Trodelvy (sacituzumab govitecan) for triple-negative breast cancer; HER3 is a differentiated payload delivery target with limited approved-drug precedent. The bispecific ADC combines the two payload-targeting mechanisms in a single molecule with the goal of expanding tumor-cell-targeting selectivity and reducing off-target toxicity relative to single-target ADCs. Pathos AI is a US oncology-focused biotech backed by AI-driven target identification and drug-discovery platforms.